OncoMatch/Clinical Trials/NCT06401356
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Is NCT06401356 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Pelabresib for hematologic malignancy.
Treatment: Pelabresib — The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Tumor Agnostic
Prior therapy
Must have received: pelabresib (pelabresib) — parent study
Previously enrolled and currently receiving pelabresib in a parent study
Cannot have received: systemic anticancer or investigational treatment
Exception: excluding parent study drug or hormonal therapy; hydroxyurea/anagrelide allowed up to 24 hours prior
Received systemic anticancer or investigational treatment (excluding parent study drug or hormonal therapy) within 2 weeks or 5 half-lives before first dose. (Hydroxyurea/anagrelide allowed up to 24 hours prior.)
Cannot have received: hematopoietic growth factors or androgenic steroids
Received hematopoietic growth factors or androgenic steroids within 4 weeks before first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology) · Los Angeles, California
- Mayo Clinic (Cancer Clinical Research Office) · Jacksonville, Florida
- Northwestern Memorial Hospital (Oncology) · Chicago, Illinois
- UMHS - University of Michigan Medical Center (Radiation Oncology) · Ann Arbor, Michigan
- Mount Sinai Hospital - Oncology · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify